Bruker (NASDAQ:BRKR) Price Target Raised to $80.00

Bruker (NASDAQ:BRKR) had its price objective hoisted by Bank of America from $78.00 to $80.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

BRKR has been the topic of a number of other reports. Barclays reduced their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. TD Cowen dropped their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Citigroup dropped their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $74.70.

Bruker Trading Down 1.3 %

NASDAQ:BRKR opened at $57.73 on Friday. The business’s 50-day moving average is $58.83 and its two-hundred day moving average is $62.71. The firm has a market capitalization of $8.75 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 4.00 and a beta of 1.18. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 earnings per share. Research analysts predict that Bruker will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be given a $0.05 dividend. The ex-dividend date is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. Bruker’s payout ratio is 9.62%.

Insider Activity at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of large investors have recently bought and sold shares of the business. SG Americas Securities LLC raised its position in shares of Bruker by 2,125.7% during the 2nd quarter. SG Americas Securities LLC now owns 27,465 shares of the medical research company’s stock worth $1,753,000 after purchasing an additional 26,231 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Bruker by 66.0% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,247 shares of the medical research company’s stock valued at $399,000 after buying an additional 2,484 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Bruker by 25.0% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 17,003 shares of the medical research company’s stock valued at $1,085,000 after acquiring an additional 3,397 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Bruker by 1,694.4% during the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company’s stock worth $12,936,000 after acquiring an additional 191,435 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Bruker by 23.1% in the 2nd quarter. Blue Trust Inc. now owns 2,569 shares of the medical research company’s stock worth $164,000 after acquiring an additional 482 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.